Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix

Summary

-list item one, The purpose of this study is to evaluate the overall response rate of belotecan (CKD-602) in recurrent or progressive carcinoma of uterine cervix

Timeline

Start

2007-01

Primary completion

2009-08

Completion

2010-10

Publications

• Hwang JH, Lim MC, Seo SS, Park SY, Kang S. Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix. Jpn J Clin Oncol. 2011 May;41(5):624-9. doi: 10.1093/jjco/hyr017. Epub 2011 Feb 24.

Drugs

Indications